COSENTYX 150 MG / 1 ML 2 PRE-FILLED PEN كوزنتكس 150 مجم / 1 مل

** Cosentyx® (secukinumab 150 mg/mL) Solution for injection in a single-use pre-filled SensoReady® pen. For subcutaneous use only. 2 pre-filled SensoReady® pens, each containing 150mg secukinumab in 1ml (300mg dose). 300 mg = 2 x 150mg.

** Composition:
1 pre-filled pen = 150 mg secukinumab
2 pre-filled SensoReady® pens, each containing 150mg secukinumab in 1ml (300mg dose). 300 mg = 2 x 150mg.

** Therapeutic indications:
– Plaque psoriasis
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
– Psoriatic arthritis
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
– Ankylosing spondylitis
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

** Pharmacotherapeutic group:
Immunosuppressants, interleukin inhibitors, ATC code: L04AC10

** Mechanism of action:
Secukinumab is a fully human IgG1/k monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions.
IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis.

** Medicinal product subject to medical prescription.

** Store at 2-8 degrees C (in a refrigerator). Do not freeze.
Store in the original package. Protect from light.
Keep out of the reach and sight of children.